Two Sigma Advisers’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Two Sigma Advisers’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-23,600	Closed	-$634K	–	2974
2022 Q1	$634K	Buy	+23,600	New	+$793K	﹤0.01%	1867
2021 Q4	–	Sell	-20,800	Closed	-$1.38M	–	2862
2021 Q3	$1.38M	Sell	20,800 -90,000	-81%	-$6.41M	﹤0.01%	1459
2021 Q2	$8.64M	Sell	110,800 -6,200	-5%	-$458K	0.02%	628
2021 Q1	$11.1M	Buy	117,000 +20,100	+21%	+$2.39M	0.03%	540
2020 Q4	$11.8M	Buy	96,900 +63,000	+186%	+$6.9M	0.03%	512
2020 Q3	$2.96M	Buy	33,900 +11,800	+53%	+$822K	0.01%	968
2020 Q2	$1.43M	Buy	+22,100	New	+$1.27M	﹤0.01%	1398

Other funds holding TPTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Two Sigma Advisers's TPTX Position: Q2 2022 in Review

Two Sigma Advisers sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q2 2022, closing a stake of 23,600 shares — an estimated $634K sold.

Two Sigma Advisers first reported a position in TPTX in Q2 2020 and held it in 7 quarters. The position peaked at $11.8M in Q4 2020. 208 funds tracked by Wall St. Rank hold TPTX as of Q2 2022.

Two Sigma Advisers reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Two Sigma Advisers sold 23,600 Turning Point Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $634K.
Two Sigma Advisers first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2020 and held it in 7 quarters.
Two Sigma Advisers's Turning Point Therapeutics, Inc. Common Stock position peaked at $11.8M in Q4 2020.
208 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Two Sigma Advisers's 13F filing for Q2 2022, filed 15 Aug 2022.